Medinice S.A., a medical technology company, creates, develops, and commercializes minimally invasive solutions in cardiology and cardiac surgery. The company offers PacePress, a medical device to reduce the risk of complications following the implantation of cardiac electrotherapeutic devices, such as pacemakers or implantable cardioverter-defibrillators; CoolCryo, a cardiac cryoablation technology that uses liquid nitrogen as the cooling medium; and AtriClamp, a clip designed to close the left atrial appendage to minimize the risk of stroke in patients with atrial fibrillation. It also provides MiniMax, an ablation-mapping catheter used for detecting intracardiac electrophysiological signals, creating a 3D map of the heart, and performing intracardiac irrigated RF ablation to treat arrhythmias caused by abnormalities in the heart’s conduction system; and EP Bioptom, an electrode for endomyocardial biopsy using 3D mapping enabling simultaneous biopsy and creation of a three-dimensional heart map. The company was founded in 2012 and is headquartered in Warsaw, Poland.
Metrics to compare | ICEP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipICEPPeersSector | |
|---|---|---|---|---|
P/E Ratio | 14.8x | 0.1x | −0.4x | |
PEG Ratio | 0.02 | 0.09 | 0.00 | |
Price/Book | 7.1x | 3.1x | 2.6x | |
Price / LTM Sales | 29,130.7x | 9.9x | 3.1x | |
Upside (Analyst Target) | - | 54.0% | 57.3% | |
Fair Value Upside | Unlock | 8.4% | 8.0% | Unlock |